Our management team brings a wealth of experience from the biotech, pharmaceutical, human and animal health sectors – as well as first hand experience establishing, marketing and raising capital for a range of successful businesses in Australia, Asia and the US. What they all have in common is a shared belief in the future of the diagnostic testing market and a joint commitment to the ongoing success of Genetic Technologies.
Eutillio Buccilli, CPA
Chief Executive Officer
Mr Buccilli was appointed to the role of Chief Financial Officer on June 2nd, 2014 and then in November appointed Chief Operating Officer. On February 26th, 2015 he was appointed Chief Executive Officer. He brings with him more than 35 years of senior management experience in the financial services, contracting and recruitment, property and retail industries in Australia and the USA. Mr Buccilli has held senior management positions with blue chip corporations such as General Electric, Computer Science Corporation, Coles Myer and Challenger Limited. Whilst with GE, Mr Buccilli was seconded to their USA headquarters in Stamford Connecticut. He brings a significant level of expertise including financial, corporate governance and commercial experience, with a strong emphasis on financial and corporate management.
Kevin Fischer, CPA,AGIA,ACIS
Chief Financial Officer & Company Secretary
Mr Fischer,was appointed to the role of Chief Financial Officer on November 2nd, 2015 and on January 13, 2016 was appointed Company Secretary. He has over ten years experience in senior finance roles with successful diagnostic companies, such as QIAGEN and Cellestis, and is well qualified to take on the roles of CFO and joint Company Secretary. Mr Fischer is a CPA and Chartered Secretary who has significant experience in the administration, financial management and reporting for international operations similar to those of Genetic Technologies.
Richard Allman, PhD
Dr Allman brings over 20 years of scientific and research experience in both the academic arena in the UK and the commercial sector in Australia. He has wide experience in research leadership, innovation management, and intellectual property strategy, covering oncology, diagnostics, and product development. Most recently he was responsible for providing scientific and technical guidance for the launch of the BREVAGen™ risk assessment test to the US market and managing both in-house research programs and external collaborative research projects, which include major academic units and commercial partners. Prior to entering the biotech sector, Dr Allman’s academic career encompassed oncology research, drug development, and assay design, with a particular interest in the linkage between onco-genetic profile and treatment response.
Chris Saunders, M.B.A., B.S.
Vice President Sales & Marketing – Phenogen Sciences Inc.
Mr. Saunders brings more than 15 years of experience in senior sales, operations and marketing roles for start-up, publicly held and multi-national companies in the pharmaceutical and biotech sectors. He served as National Sales Director at Cbr Systems, a cord blood stem cell bank that serves customers in the United States and internationally. Most recently, he served as an early sales management leader at Natera, a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. During his tenure, he successfully launched new products and product expansions through multiple channels including private practice, hospital, health system and distribution partnerships. Areas of expertise include business development, sales operations, training and management strategies focused on sales growth and market expansion.
Susan J Gross, MD, FRCSC, FACOG, FACMG
Senior Medical Director – Phenogen Sciences Inc.
Dr Gross was appointed to the role of Senior Medical Director in June 2016.Dr. Gross received her medical degree from the University Of Toronto, Ontario, Canada, where she completed her residency in Obstetrics and Gynecology, as well as a fellowship in Maternal Fetal Medicine and a second residency/fellowship in Medical Genetics at the University of Tennessee (Memphis). She is board certified in both Obstetrics and Gynecology and Medical Genetics and is a Professor of Clinical Obstetrics & Gynecology, Women’s Health, Pediatrics and Genetics at the Albert Einstein College of Medicine. She served as past division director for the division of Reproductive Genetics at Montefiore Medical Center as well as Chairperson of the Department of Obstetrics and Gynecology and founder of the Human Genetics Laboratory at Jacobi Medical Center. Dr. Gross has spent decades not only in research and medical education, but also direct patient care, overseeing both large and small practice systems. She has worked on national and international guideline committees and lectured and published extensively on screening and genetic testing with a focus on new technologies and public health policy. She was previously the Chief Medical Officer of Natera Inc., a public genomic diagnostics company and is now President of SJG Advisors LLC, a company that provides comprehensive medical affairs and digital media expertise to the diagnostics industry. .
Quality and Business Operations Director
Ms Newport,was appointed as Quality and Business Operations Director in September 2013. She comes to the Company with extensive international Quality Systems and operational experience in the highly regulated industries of food and pharmaceutical. The Company will benefit from her recent senior role within the CSL quality control laboratories.